Finally, the concentrations of CXCL10 were also increased in patients with ongoing first-line DMD treatment in comparison to untreated patients (P < 0.01) and patients treated with second-line DMDs (P < 0.01). This evidence concerns the gene CXCL10 and Duchenne muscular dystrophy.